Southwest Airlines Q3 Profit Beats Estimates

Southwest Airlines Co. (LUV) said revenue trends remained strong in September 2022, bolstered by improving business travel trends post-Labor Day. The company currently expects revenue trends to improve sequentially from third quarter to fourth quarter 2022, despite lower capacity. Southwest Airlines expects to generate strong profits and margins in fourth quarter 2022, based on current trends.

Third quarter net income per share, excluding special items, was $0.50 compared to a loss of $0.23, prior year. On average, 14 analysts polled by Thomson Reuters expected the company to report profit per share of $0.42, for the quarter. Analysts' estimates typically exclude special items.

Net income was $277 million or $0.44 per share compared to $446 million or $0.73 per share, prior year.

Third quarter operating revenues were $6.2 billion, an increase of 32.9% from last year. Analysts on average had estimated $6.21 billion in revenue. Operating revenues were up 10.3 percent compared with third quarter 2019, in line with the company's previous guidance.

Shares of Southwest Airlines are up 3% in pre-market trade on Thursday.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT